Brief: CanSino Biologics Gets Approval For Clinical Trial On Tetanus Vaccine
27/07/2023 11:46
July 27 (Reuters) - CanSino Biologics Inc
688185.SS 6185.HK :
* SAYS IT GETS CHINESE MEDICINE REGULATOR'S APPROVAL FOR
CLINICAL
TRIAL ON TETANUS VACCINE
Source text
Further company coverage: 688185.SS
(Reporting by Hong Kong newsroom)
((meg.shen@thomsonreuters.com; 852-39525805;))
Recent news on Cansino Biologics
See all newsBrief: CanSino Biologics Says China's NMPA Granted Priority Review Status To NDA For TD5CP Adolescent, Adult
Brief: CanSino Biologics Reports Widened Net Loss For Q1
Brief: CanSino Biologics Says 2025 Net Profit At 27.9 Million Yuan
Brief: CanSino Biologics Prelim 2025 Net Profit At 27.9 Million Yuan
Brief: CanSino Biologics Expects To Have Returned to Net Profit In 2025